Top Markets
Coin of the day
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals, Inc.

PRTK
株式のランク #21736
Paratek Pharmaceuticals, Inc., a biopharmaceutical firm headquartered in... Paratek Pharmaceuticals, Inc., a biopharmaceutical firm headquartered in Boston, Massachusetts, and founded in 1996, is actively engaged in the commercialization of its products. The company's core mission involves the creation and market introduction of crucial medical treatments for severe illnesses or major public health crises, intended for civilian, governmental, and military applications. Their flagship therapeutic offerings include NUZYRA and SEYSARA. NUZYRA is a comprehensive, once-daily antibiotic, available in both oral and intravenous forms, prescribed for adult patients battling community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens. SEYSARA, a medication derived from the tetracycline class, is specifically formulated to address moderate to severe cases of acne vulgaris. Beyond its internal development, Paratek maintains several strategic alliances. This includes licensing and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc. The company also holds a license from Tufts University, enabling the development and commercialization of solutions for bacterial or microbial diseases. Furthermore, a significant contract with the Biomedical Advanced Research and Development Authority (BARDA) is in place to advance NUZYRA for treating pulmonary anthrax. Additionally, Paratek has a licensing agreement with Tetraphase Pharmaceuticals, Inc. to oversee the development, import, and sale of the XERAVATM product, utilized for complicated intra-abdominal infections of bacterial origin.
株価
$2.23
最終同期: 2023-09-29
時価総額
$101.43M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Paratek Pharmaceuticals, Inc. (PRTK)

カテゴリー

Paratek Pharmaceuticals, Inc.(PRTK)の配当履歴
Paratek Pharmaceuticals, Inc.(証券コード:PRTK)は合計で0回の配当を行いました。
すべての配当の合計(株式分割調整済み)は:0.00
配当利回り(TTM):0
2026から2026までのParatek Pharmaceuticals, Inc.(PRTK)の配当履歴
年間配当支払い
配当(株式分割調整済み) 変化
提供された日付のデータは十分ではありません。
すべての配当支払いの一覧
配当 変化
提供された日付のデータは十分ではありません。
同業他社や競合企業の配当履歴
企業 配当支払い回数
0.00%
US
0.00%
NL
0.00%
US
64.00%
AU
0.00%
CH